The transaction, slated to finalize in the fourth quarter, carries an immediate financial impact, with Gilead projecting a dilution of its quarterly earnings per share by approximately 79 to 83 cents. The company intends to advance the clinical development of HCXT-2001, exploring its efficacy both as a standalone therapy and in combination with existing assets in its pipeline. Chief Medical Officer Dietmar Berger characterized the acquisition as a vital step in expanding the firm’s inflammation portfolio, citing the potential for a differentiated oral approach to address significant unmet medical needs.